Nephrogenic systemic fibrosis following exposure to gadolinium-containing contrast agent

被引:0
|
作者
Clorius, S.
Technau, K.
Watter, T.
Schwertfeger, E.
Fischer, K.-G.
Walz, G.
Gerke, P.
机构
[1] Univ Hosp Freiburg, Div Renal, D-79106 Freiburg, Germany
[2] Univ Hosp Freiburg, Dept Dermatol, Freiburg, Germany
[3] Ctr Nephrol & Hypertens, Freiburg, Germany
关键词
nephrogenic fibrosing; dermopathy; gadolinium; dialysis; scleroderma; skin thickening; kidney failure;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Nephrogenic systemic fibrosis (NSF) is a disease recently described in patients with kidney failure. It is characterized by scleroderma-like thickening of the skin, subcutaneous edema and ensuing joint contractures leading to profound disability. Furthermore, involvement of internal organs has been described. Whereas the pathogenesis is not known to date, recent reports have linked NSF to high doses of gadolinium-containing contrast agents given at magnetic resonance angiography (MRA). We describe a patient with severe NSF. The patient had received erythropoietin and had undergone vascular interventions which are suspected risk factors for this disease. Notably, the disease developed shortly after the application of gadolinium at an MRA, giving support to the recently published hypothesis that gadolinium-containing contrast agents are among the causative factors. We provide a short overview and hope to raise overall awareness towards this entity and the use of MRA contrast agents in renal patients.
引用
收藏
页码:249 / 252
页数:4
相关论文
共 50 条
  • [41] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Penfield, Jeffrey G.
    PEDIATRIC NEPHROLOGY, 2008, 23 (12) : 2121 - 2129
  • [42] Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis
    Kuo, Phillip H.
    Kanal, Emanuel
    Abu-Alfa, Ali K.
    Cowper, Shawn E.
    RADIOLOGY, 2007, 242 (03) : 647 - 649
  • [43] Nephrogenic systemic fibrosis and the use of gadolinium-based contrast agents
    Jeffrey G. Penfield
    Pediatric Nephrology, 2008, 23 : 2121 - 2129
  • [44] Gadolinium-based Contrast Agents and Nephrogenic Systemic Fibrosis Response
    Semelka, Richard C.
    Altun, Ersan
    Wertman, Rebecca
    Martin, Diego R.
    Leyendecker, John R.
    O'Malley, Ryan B.
    Parsons, Daniel J.
    Fuller, Edwin R., III
    Mitchell, Donald G.
    RADIOLOGY, 2009, 250 (03) : 959 - U457
  • [45] Complications of nephrogenic systemic fibrosis following repeated exposure to gadolinium in a man with hypothyroidism: A case report
    Aggarwal A.
    Froehlich A.A.
    Essah P.
    Brinster N.
    High W.A.
    Downs R.W.
    Journal of Medical Case Reports, 5 (1)
  • [46] Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure
    Bernstein, Elana J.
    Schmidt-Lauber, Christian
    Kay, Jonathan
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2012, 26 (04): : 489 - 503
  • [47] Advancing pharmacovigilance through analysis of a gadolinium-based contrast agent (GBCA) exposure dataset for nephrogenic systemic fibrosis: A RADAR report
    Nardone, Beatrice
    Laumann, Anne E.
    Edwards, Beatrice J.
    West, Dennis P.
    Belknap, Steven M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB5 - AB5
  • [48] Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?
    Rosenkranz, Alexander R.
    Grobner, Thomas
    WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 (9-10) : 271 - 275
  • [49] Conventional or Gadolinium containing contrast media: the choice between acute renal failure or Nephrogenic Systemic Fibrosis?
    Alexander R. Rosenkranz
    Thomas Grobner
    Gert J. Mayer
    Wiener klinische Wochenschrift, 2007, 119 : 271 - 275
  • [50] Nephrogenic systemic fibrosis - gadolinium disease?
    Economidou, D.
    Pateinakis, P.
    ARCHIVES OF HELLENIC MEDICINE, 2009, 26 (05): : 593 - 600